Second-generation drug-eluting stents and bioresorbable vascular scaffolds in patients with diabetes

JACC: Cardiovascular Interventions

Volumn 7, Issue 5, 2014, Pages 494-496

  Schoos, Mikkel M ^a   Clemmensen, Peter ^a   Dangas, George D ^b  

^a University of Copenhagen   (Denmark)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

bioresorbable scaffold; coronary artery disease; diabetes mellitus; drug eluting stent

Indexed keywords

CHROMIUM; COBALT; EVEROLIMUS; INSULIN; PACLITAXEL; RAPAMYCIN; ZOTAROLIMUS; FATTY ACID; POLYMER; CARDIOVASCULAR AGENT;

ATHEROSCLEROSIS; BIORESORBABLE SCAFFOLD; BIORESORBABLE VASCULAR SCAFFOLD; BIORESORBABLE VASCULAR STENT; CLINICAL TRIAL (TOPIC); CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC PATIENT; DRUG ELUTING STENT; EVEROLIMUS ELUTING STENT; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERGLYCEMIA; IN-STENT RESTENOSIS; NOTE; PACLITAXEL ELUTING STENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROPENSITY SCORE; RAPAMYCIN ELUTING STENT; TREATMENT OUTCOME; ZOTAROLIMUS ELUTING STENT; BARE METAL STENT; CELL MIGRATION; CELL PROLIFERATION; COMORBIDITY; CORONARY ARTERY BYPASS GRAFT; ENDOTHELIAL DYSFUNCTION; FOLLOW UP; GLYCOSYLATION; HEART DEATH; HEART INFARCTION; INCIDENCE; INSULIN RESISTANCE; LONG TERM CARE; OUTCOME ASSESSMENT; PLATELET REACTIVITY; SECONDARY PREVENTION; SHEAR STRESS; SMOOTH MUSCLE FIBER; STENT COMPLICATION; STENT THROMBOSIS; VASODILATATION; ANALOGS AND DERIVATIVES; BIODEGRADABLE IMPLANT; COMPLICATION; CORONARY STENOSIS; DEVICES; DIABETIC ANGIOPATHIES; FEMALE; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS;

ABSORBABLE IMPLANTS; CARDIOVASCULAR AGENTS; CORONARY ARTERY DISEASE; CORONARY STENOSIS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; PERCUTANEOUS CORONARY INTERVENTION; SIROLIMUS;

EID: 84901281178     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2014.01.156     Document Type: Editorial

References (10)

1. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): Diagnosed and Undiagnosed Diabetes among People Ages 20 Years or Older, United States, 2010. Available at: http://diabetes.niddk.nih.gov/dm/pubs/statistics/ #Diagnosed20, 2011. Accessed April 10, 2014.
2. J.E. Shaw, R.A. Sicree, and P.Z. Zimmet Global estimates of the prevalence of diabetes for 2010 and 2030 Diabetes Res Clin Pract 87 2010 4 14
3. E.J. Armstrong, J.C. Rutledge, and J.H. Rogers Coronary Artery Revascularization in Patients With Diabetes Mellitus Circulation 128 2013 1675 1685
4. M. Roffi, D.J. Angiolillo, and A.P. Kappetein Current concepts on coronary revascularization in diabetic patients Eur Heart J 32 2011 2748 2757
5. M.E. Farkouh, M. Domanski, and L.A. Sleeper et al. Strategies for multivessel revascularization in patients with diabetes N Engl J Med 367 2012 2375 2384
6. T. Muramatsu, Y. Onuma, and R.-J. van Geuns et al. One-year clinical outcomes of diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds: a pooled analysis of the ABSORB and the SPIRIT trials J Am Coll Cardiol Intv 7 2014 482 493
7. K.W. Park, J.M. Lee, and S.-H. Kang et al. Everolimus-eluting Xience V/Promus versus zotarolimus-eluting Resolute stents in the patients with diabetes mellitus J Am Coll Cardiol Intv 7 2014 471 481
8. G.W. Stone, E. Kedhi, and D.J. Kereiakes et al. Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus Circulation 124 2011 893 900
9. Y. Onuma, and P.W. Serruys Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization? Circulation 123 2011 779 797
10. E. Grube, B. Chevalier, and G. Guagliumi et al. The SPIRIT V diabetic study: a randomized clinical evaluation of the XIENCE V everolimus-eluting stent vs the TAXUS Liberté paclitaxel-eluting stent in diabetic patients with de novo coronary artery lesions Am Heart J 163 2012 867 875.e1